[en] Background and aims: Infliximab (IFX) has been shown efficacious for moderate-to-severe ulcerative colitis (UC), but data on long-term efficacy are tacking. We investigated long-term outcome including colectomy rates in outpatients treated with IFX for refractory UC in a single referral centre, and evaluated if predictors could be identified. Methods: The first 121 outpatients (median age 38.0 years) with refractory UC treated with IFX were included. The primary outcome was colectomy-free survival. Secondary measures were sustained clinical response and serious adverse events. Results: From the 81 patients (67%) with an initial clinical response to IFX, 68% had a sustained clinical response. No independent predictors of sustained clinical response could be identified. Over a median (IQR) follow-up period of 33.0 (17.0-49.8) months, 21 patients (17%) came to colectomy. Independent predictors of colectomy were absence of short-term clinical response [Hazard ratio 10.8 (95% Cl 3.5-32.8), p < 0.001], a baseline CRP level >= 5 mg/L [Hazard ratio 14.5 (95% Cl 2.0-108.6), p=0.006] and previous IV treatment with corticosteroids and/or cyctosporine [Hazard ratio 2.4 (95% Cl 1.1-5.9), p=0.033]. Six patients developed a serious infection, three a malignancy, two a post-operative complication and one patient died (suicide). Conclusions: With a median follow-upof 33.0 months after start of IFX, 17% of patients with refractory UC needed colectomy, while sustained clinical response was present in 68% of initial responders. (c) 2008 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Ferrante, M.
Vermeire, S.
Fidder, H.
Schnitzler, F.
Noman, M.
Van Assche, G.
De Hertogh, G.
Hoffman, I.
D'Hoore, A.
Van Steen, Kristel ; Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Hanauer S.B. Medical therapy for ulcerative colitis 2004. Gastroenterology 126 6 (2004) 1582-1592
Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 23 (8-12-2005) 2462-2476
Ferrante M., Vermeire S., Katsanos K.H., et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 13 2 (2007) 123-128
Mcgovern D.P.B., Ahmad T., van Heel D., and Jewell D.P. A genetic panel strongly predicts the need for colectomy in ulcerative colitis. Gastroenterology 126 4 (2004) A68
Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 Suppl A (2005) 5-36
Schroeder K.W., Tremaine W.J., and Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317 26 (24-12-1987) 1625-1629
Beaugerie L., Massot N., Carbonnel F., Cattan S., Gendre J.P., and Cosnes J. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol 96 7 (2001) 2113-2116
Selvasekar C.R., Cima R.R., Larson D.W., et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204 5 (2007) 956-962
Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab in the treatment of inflammatory bowel disease: a single center cohort study. J Crohn's Colitis Suppl 1 1 (2007) 3
Jakobovits S.L., Jewell D.P., and Travis S.P.L. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford From 2000 to 2006. Aliment Pharmacol Ther 25 9 (1-5-2007) 1055-1060
Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 9317 (4-5-2002) 1541-1549
Parsi M.A., Achkar J.P., Richardson S., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123 3 (2002) 707-713
Vermeire S., Louis E., Carbonez A., et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 97 9 (2002) 2357-2363
Travis S. Review article: saving the colon in severe colitis - the case for medical therapy. Aliment Pharmacol Ther 24 (2006) 68-73
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.